Skip to main content

Clinical Trial Simulations

Modeling & Simulation Webinar

Clinical Trial Simulations: An Efficient Tool for Improved Study Designs, Dose Selection and Go/No-go Investment Decisions, by Per Olsson and Alberto Russu.
Europe: Tuesday 19/09 at 3pm CEST.
US: Thursday 28/09 at 9am CDT.

In silico evaluation of pharmacokinetic optimization for antimitogram-based clinical trials

Through collaboration with the university of Lyon, Simulo was intensively used to simulate and optimize antimitogram-based clinical trials. The result is an impressive simulation-based paper published in the journal for American Association for Cancer Research.

Two-day Clinical Trial Simulation course at PAGE 2018

In the context of the next PAGE meeting, SGS Exprimo is running a two-day Clinical Trial Simulation course on Monday and Tuesday 28-29 May.

Clinical Trial Simulation course at University of Lyon

Ruben Faelens from SGS Exprimo teached a 4-hour session at the Master Pharmacology, Modeling and Clinical trials (PHAME) at the University Claude Bernard Lyon 1, using Simulo!

SGS Exprimo delegation at ACoP 2017

SGS Exprimo will be present at the American Conference on Pharmacometrics, 15-18 October in Fort Lauderdale. Come visit our booth to learn more about our consulting services. We will also demonstrate the Simulo software for clinical trial and dosing simulations.

Public Clinical Trial Simulation course in collaboration with Freie Universität Berlin

SGS Exprimo is running a public two-day Clinical Trial Simulation course on Thursday and Friday 2-3 November in Germany, together with Professor Charlotte Kloft’s team at Freie Universität Berlin.

Two-day Clinical Trial Simulation course at PAGE 2017

In the context of the PAGE meeting, SGS Exprimo ran a two-day satellite course on Monday and Tuesday 5-6 June.

Time-to-Seizure Modeling of Lacosamide Used in Monotherapy in Patients with Newly Diagnosed Epilepsy

Baseline disease severity was the most important predictor of seizure probability. Simulations suggest that an initial target dose >200 mg/day could potentially benefit patients with greater disease severity.

How can modelling and simulation optimize the clinical development of biosimilars?

Bernardo de Miguel Lillo explores the competitive advantages SGS Exprimo can offer in the development of biosimilars

Simulo Press Release

SGS Exprimo officially launches Simulo platform to provide modeling and simulation solutions for clinical trial design optimization.

How can we help you?